News Sentiment

KROS sentiment intelligence

Keros Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.65 Week of 19 Jun 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+4.9% over one week, -4.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 4.9% Price confirming higher
Trend fit Trend inactive -4.8% over four weeks
Fair value -65.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 24
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 7
TradingKey 4
simplywall.st 4
TradingView 3
Stock Traders Daily 2
MarketBeat 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 15
Analyst action 4
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TradingKey Direct company coverage

Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Keros Therapeutics Inc (KROS), noting its current valuation score is 7.27, ranking 244 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.21, and mentions that relevant data for P/

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 02:09
Source
TradingKey
Stock Traders Daily Direct company coverage

(KROS) Movement Within Algorithmic Entry Frameworks

Keros Therapeutics Inc. (NASDAQ: KROS) is showing a mid-channel oscillation pattern with strong near-term sentiment that could challenge persistent mid and long-term weakness. Algorithmic analysis highlights an exceptional 112.7:1 risk-reward setup targeting a 35.7% gain against

Tone
Positive 70/100
Event
Market update
Published
19 Jun 2026 00:09
Source
Stock Traders Daily
MarketBeat Direct company coverage

Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS

Madison Avenue Partners LP significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 69.6% in the fourth quarter of 2025. This institutional activity occurred alongside insider selling and a weaker-than-expected quarterly earnings report from Keros Therapeutics. Desp

Tone
Negative 29/100
Event
Earnings
Published
18 Jun 2026 11:40
Source
MarketBeat
TradingKey Direct company coverage

Keros Therapeutics Inc (KROS) Institutional Confidence

This article analyzes the institutional confidence in Keros Therapeutics Inc (KROS), noting its current institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quart

Tone
Positive 69/100
Event
Market update
Published
18 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Keros Therapeutics Inc (KROS), highlighting its current price momentum score of 6.27 within the Biotechnology & Medical Research industry. It details the stock's trading range between resistance at $11.46 and support at $9.52, and pre

Tone
Negative 29/100
Event
Market update
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Keros Therapeutics Inc (KROS), covering business segments, regional revenue, and profit contribution. It notes that relevant data for these categories have not yet been disclosed by the company. The current stock price of KROS is pro

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
Stock Titan Direct company coverage

Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan

Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock at a weighted average price of $10.19 per share. This open-market transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, meaning it was pre-scheduled. Followin

Tone
Positive 60/100
Event
Market update
Published
17 Jun 2026 20:39
Source
Stock Titan
Investing.com Direct company coverage

Keros Therapeutics director Charles W. Newton sells $5,521 in shares

Keros Therapeutics director Charles W. Newton sold 550 shares of the company's common stock for a total of $5,521 on June 11, 2026. The sale was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week low. Despite the recent price decli

Tone
Negative 36/100
Event
Market update
Published
16 Jun 2026 00:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com

Charles W. Newton, a director at Keros Therapeutics, Inc. (NASDAQ:KROS), sold 550 shares of the company’s common stock for a total of $5,521. The sale occurred on June 11, 2026, with shares trading between $9.83 and $10.16. Despite the stock being near its 52-week low and down 52

Tone
Negative 33/100
Event
Market update
Published
15 Jun 2026 21:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade

Keros Therapeutics director Charles W. Newton sold 550 shares of common stock at a weighted average price of $10.04 per share, a transaction conducted on June 11, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Newton directly holds 12,665 shares of Kero

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside

Keros Therapeutics, Inc.'s average price target has been reduced from $21.83 to $20.2 by 5 analysts, with forecasts ranging from $16 to $25 per share. This new target implies a potential upside of approximately 99% based on the June 12 closing price. The consensus rating for the

Tone
Positive 71/100
Event
Analyst action
Published
13 Jun 2026 05:20
Source
TradingView
Stock Titan Direct company coverage

[144] Keros Therapeutics, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Keros Therapeutics, Inc. (KROS). The filing details the proposed sale of 550 shares of common stock by an individual, acquired through an RSU on May 15, 2026, with an aggregate market value of $5,472.50. The shares are expected to

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:09
Source
Stock Titan
Investing.com Direct company coverage

Keros Therapeutics director Nima sells $28,166 in company stock

Nima Farzan, a director at Keros Therapeutics, sold 2,625 shares of company stock worth $28,166 on June 4, 2026, under a pre-arranged trading plan. This transaction occurred while the stock was trading near its 52-week low and had declined significantly over the past six months.

Tone
Negative 37/100
Event
Market update
Published
09 Jun 2026 06:09
Source
Investing.com
GuruFocus Direct company coverage

Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS)

Alpna Seth, a Director at Keros Therapeutics Inc (KROS), sold 2,625 shares of the company on June 4, 2026. This transaction leaves her with 9,767 shares. Keros Therapeutics is a clinical-stage biopharmaceutical company, and its stock was trading at $10.72 per share on the day of

Tone
Negative 33/100
Event
Market update
Published
05 Jun 2026 22:38
Source
GuruFocus
Stock Titan Direct company coverage

Keros Therapeutics director granted RSUs and options | KROS Insider Trading

Keros Therapeutics director Alpna Seth was granted 7,142 restricted stock units (RSUs) and a stock option for 7,433 shares with an exercise price of $10.50, as reported in a recent Form 4 filing. This compensation-related grant means she did not purchase shares on the open market

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:38
Source
Stock Titan
Stock Titan Direct company coverage

Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant

Keros Therapeutics director Jean Jacques Bienaime received 7,142 restricted stock units (RSUs) and options for 7,433 shares of Common Stock with an exercise price of $10.50 per share. These equity awards are compensation-related and not open-market trades. Following the grant, Bi

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards

Keros Therapeutics director Mary Ann Gray was granted 7,142 restricted stock units (RSUs) and options for 7,433 shares at an exercise price of $10.50. The RSUs vest by June 3, 2027, or the 2027 annual meeting, while the stock options vest quarterly over 12 months after June 3, 20

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan

Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 common shares at a weighted average price of $10.72 per share on June 4, 2026. The sale, made between $10.60 and $10.89, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 9,

Tone
Negative 39/100
Event
Market update
Published
05 Jun 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Keros Therapeutics, Inc. SEC Filing

This article reports on Keros Therapeutics, Inc.'s SEC Form 144 filing, indicating a proposed sale of securities. The document details the filer and issuer information, the nature of the securities to be sold (Common Stock), and their acquisition details, noting a neutral impact

Tone
Neutral 50/100
Event
Deals and strategy
Published
04 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay

Keros Therapeutics (NASDAQ: KROS) stockholders approved all proposals at their 2026 Annual Meeting. Key decisions included the election of Jean-Jacques Bienaimé and Charles Newton as directors, the ratification of Deloitte & Touche LLP as the company's independent auditor for 202

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 19:39
Source
Stock Titan
TradingView Direct company coverage

Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside

Keros Therapeutics, Inc. (KROS) has seen its average 12-month price target adjusted downwards to $21.83 from $22.2, according to estimates from six analysts. Despite the cut, this new target still suggests approximately 107% potential upside based on the June 2nd closing price. T

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jun 2026 17:39
Source
TradingView
GlobeNewswire Direct company coverage

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Keros Therapeutics, Inc. announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 15:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat

Keros Therapeutics announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. The company is a clinical-stage biopharmaceutical firm focusing on therapeutics

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 19:39
Source
Stock Titan
Stock Traders Daily Direct company coverage

Trading Systems Reacting to (KROS) Volatility

Keros Therapeutics Inc. (NASDAQ: KROS) is experiencing volatility with strong near-term sentiment potentially challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with a m

Tone
Positive 61/100
Event
Market update
Published
27 May 2026 21:20
Source
Stock Traders Daily
The Globe and Mail Direct company coverage

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros Therapeutics (KROS) is focusing on its lead neuromuscular program, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) in 2026. The drug aims to modulate transforming growth factor-beta family signaling to promote muscle gro

Tone
Positive 67/100
Event
Market update
Published
22 May 2026 16:09
Source
The Globe and Mail
Streetwise Reports Direct company coverage

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles

Keros Therapeutics (KROS:NASDAQ) announced that the initiation of its Phase 2 rinvatercept study for Duchenne muscular dystrophy (DMD) will be delayed from Q2 2026 to Q3 2026 due to procedural regulatory hurdles. Wedbush Securities analyst Yun Zhong reiterated a Neutral rating wi

Tone
Negative 38/100
Event
Analyst action
Published
20 May 2026 16:09
Source
Streetwise Reports